Sangamo Therapeutics, Inc. Forecast, price target & analysts
Sangamo Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Sangamo Therapeutics, Inc. Classifications & Recommendation:
Sangamo Therapeutics, Inc. Price Target
| Target Price | $5.80 |
| Price | $0.96 |
| Potential |
506.00%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Sangamo Therapeutics, Inc. 2026 .
The average Sangamo Therapeutics, Inc. target price is $5.80.
This is
506.00%
register free of charge
$10.00
944.82%
register free of charge
$2.00
108.96%
register free of charge
|
|
| A rating was issued by 8 analysts: 5 Analysts recommend Sangamo Therapeutics, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sangamo Therapeutics, Inc. stock has an average upside potential 2026 of
506.00%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 176.23 | 61.65 |
| 58.34% | 65.02% | |
| EBITDA Margin | -52.26% | -155.15% |
| 69.25% | 196.87% | |
| Net Margin | -175.20% | -159.61% |
| 25.22% | 8.90% |
6 Analysts have issued a sales forecast Sangamo Therapeutics, Inc. 2024 . The average Sangamo Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Sangamo Therapeutics, Inc. EBITDA forecast 2024. The average Sangamo Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Sangamo Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Sangamo Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.48 | -0.47 |
| 18.40% | 68.24% | |
| P/E | negative | |
| EV/Sales | 3.05 |
6 Analysts have issued a Sangamo Therapeutics, Inc. forecast for earnings per share. The average Sangamo Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Sangamo Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Sangamo Therapeutics, Inc....
Current Sangamo Therapeutics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 27 2025 |
| Truist Securities | Locked ➜ Locked | Locked | Jan 23 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 02 2025 |
| Jefferies | Locked ➜ Locked | Locked | Dec 31 2024 |
| Wells Fargo | Locked ➜ Locked | Locked | Dec 31 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 20 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 19 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 27 2025 |
|
Locked
Truist Securities: Locked ➜ Locked
|
Jan 23 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 02 2025 |
|
Locked
Jefferies: Locked ➜ Locked
|
Dec 31 2024 |
|
Locked
Wells Fargo: Locked ➜ Locked
|
Dec 31 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 20 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 19 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
